Tatva Chintan Pharma Chem Ltd has scheduled a virtual one-on-one meeting with Alchemy Capital Management Pvt. Ltd. on July 28, 2026. The interaction aims to engage with the investor based on publicly available information, ensuring no unpublished price sensitive information (UPSI) is disclosed during the session.

The company clarified that discussions will be restricted to information already accessible to the public. The schedule was intimated to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company noted that the schedule is subject to change. The information regarding the meeting is available on the company's website.

Tatva Chintan Pharma Chem Ltd held the groundbreaking ceremony for its new greenfield manufacturing unit at Dahej - III, Dahej Industrial Estate, Gujarat, on July 20, 2026. This development follows the Board's approval in Q1FY27 to expand capacity to meet growing market demands. The company reported a 140% surge in consolidated net profit to ₹159.81 million for the quarter ended June 30, 2026, supported by a 43% rise in revenue from operations to ₹1,670.55 million.

The new facility at Dahej is part of a strategic expansion involving an investment of ~₹200 crore. It will add a reactor capacity of 344 kilolitres, augmenting the company's existing combined installed capacity of 791 kilolitres at Ankleshwar and Dahej SEZ. The project is expected to be completed within 21 months and will be funded through internal accruals and debt. The Board also approved increasing the company's borrowing limits from ₹300 crore to ₹1,000 crore, subject to shareholder approval.

Key Financial Metrics (Consolidated)

The table below summarises the company's consolidated financial performance for Q1FY27:

Segment and Operational Performance

Structure Directing Agents (SDA) contributed 35% of the total revenue in Q1FY27, amounting to ₹578 million. The company remains the 2nd largest manufacturer of SDAs for Zeolites globally and the largest commercial supplier in India. Phase Transfer Catalyst (PTC) and Electrolyte Salts (ESS) are other key product categories, with exports constituting 75% of revenue in FY25.

Board Decisions and Approvals

The Board approved the unaudited financial results on July 17, 2026. M/s. NDJ & Co., Chartered Accountants, the statutory auditors, issued a Limited Review Report expressing an unmodified opinion. Additionally, the Board sanctioned the re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director and Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani as Whole-time Directors for three years from February 1, 2027, subject to shareholder approval.